Development of an in silico multi-epitope vaccine against SARS-COV-2 by precised immune-informatics approaches.

ABSTRACT: The coronavirus family has been infecting the human population for the past two decades, but the ongoing coronavirus called SARS-CoV-2 has posed an enigmatic challenge to global public health security. Since last year, the mutagenic quality of this virus is causing changes to its genetic material. To prevent those situations, the FDA approved some emergency vaccines but there is no assurance that these will function properly in the complex human body system. In point of view, a short but efficient effort has made in this study to develop an immune epitope-based therapy for the rapid exploitation of SARS-CoV-2 by applying in silico structural biology and advancing immune information strategies. The antigenic epitopes were screened from the Surface, Membrane, Envelope proteins of SARS-CoV-2

SUBMITTER: Al Zamane S 

PROVIDER: S-EPMC8563510 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature